Author

Isabella Pallavicini

European Institute of OncologyORCID 0000-0002-6856-4983Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Assay:CITE-seq· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Approach:experimental assay· 1

Frequent Co-Authors

Elena CeccacciiD· 2 shared Saverio MinucciiD· 2 shared Alberto Bigogno· 1 shared Amir HosseiniiD· 1 shared Antonello MaiiD· 1 shared Carina B. Nava LausoniD· 1 shared Carlotta CatozziiD· 1 shared Chiara SorianiiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Elena CeccacciORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 6, 2026

Cell cycle control of chromatin creates a therapeutic window for epigenetic therapy in tumors

Kourosh Hayatigolkhatmi, Riccardo Valzelli, Elena Ceccacci…·Saverio Minucci

This paper shows that extending G1 phase in cancer cells creates a therapeutic window for epigenetic drugs, with LSD1 inhibition and CDK4/6 inhibition working synergistically to induce differentiation and improve survival in AML models.

DOI 10.64898/2026.09.03.748889

humanATAC-seq

𝕏 PostBluesky

ImmunologyNature CommunicationsPeer-reviewedAug 27, 2024

LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness.

Isabella Pallavicini, Teresa Maria Frasconi, Carlotta Catozzi…·Teresa Manzo

This study shows that inhibiting LSD1 enhances CD8+ T cell function in adoptive T cell therapy, leading to improved antitumor immunity and synergistic effects with anti-PDL1 therapy.

22 citations

mouseCITE-seq

𝕏 PostBluesky